Mizuho lowered the firm’s price target on Evolus (EOLS) to $19 from $20 and keeps an Outperform rating on the shares. The firm reduced Jeuveau and Evolysse estimates citing the recent downdraft in consumer sentiment. It now sees increased likelihood of persistent inflationary pressure on demand for injectable facial aesthetic procedures. However, Evolus continues to have “compelling” long-term prospects, the analyst tells investors in a research note.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EOLS:
- Evolus’s Strategic Growth and Market Resilience Drive Buy Rating
- Evolus, Inc. Earnings Call Highlights Growth and Resilience
- Evolus price target raised to $20 from $19 at Mizuho
- Evolus’s Strategic Resilience and Growth Amidst Market Challenges: A Buy Recommendation
- Evolus Maintained at Hold Amid Mixed Financial Performance and Market Challenges